Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/29/2025

IV to PO Furosemide Conversion for Heart Failure Exacerbation

Conversion Principles

  • The European Society of Cardiology guidelines specify that the initial IV dose should be at least equal to the pre-existing oral dose used at home, suggesting an oral equivalent of approximately 320mg daily for a patient on 160mg IV furosemide 1, 2
  • Furosemide has variable oral bioavailability, which is why some patients respond more favorably to other loop diuretics like bumetanide or torsemide due to their increased oral bioavailability 3

Safety Considerations

  • Diuretics can cause depletion of potassium and magnesium, predisposing to serious cardiac arrhythmias, and this risk is markedly enhanced when two diuretics are used in combination 3
  • Regular monitoring of renal function and electrolytes is essential during diuretic therapy, as inappropriately high doses can lead to volume contraction, increasing risk of hypotension and renal insufficiency 3, 4
  • If systolic BP falls below 90 mmHg, temporarily hold or reduce the furosemide dose, and avoiding high doses in patients with hypotension is recommended, although the specific guideline from Praxis Medical Insights is not preferred, the concept is supported by the need to monitor blood pressure closely 3, 4

Post-Discharge Management

  • Patients should record daily weights and adjust diuretic dosage if weight increases or decreases beyond a specified range, and once fluid retention resolves, continue diuretic therapy to prevent recurrence of volume overload 3
  • If resistance develops, consider adding thiazide diuretics or aldosterone antagonists rather than escalating to very high furosemide doses, as combinations in low doses are often more effective with fewer side effects 1, 6

Common Pitfalls to Avoid

  • Using inappropriately low doses will result in fluid retention and potential readmission, and in case of worsening chronic HFrEF, every attempt should be made to continue evidence-based therapies in the absence of hemodynamic instability 3, 4
  • Avoid NSAIDs or COX-2 inhibitors as they increase risk of HF worsening and hospitalization 4

REFERENCES